Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941665 | PMC |
| http://dx.doi.org/10.4244/EIJ-E-23-00052 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fluorofurimazine, a novel NanoLuc substrate, enhances real-time tracking of influenza A virus infection without altering pathogenicity in mice.
Microbiol Spectr
January 2025
Department of Microbiology and Immunology, Frederick P. Whiddon College of Medicine, University of South Alabama, Mobile, Alabama, USA.
Unlabelled: Bioluminescence imaging (BLI) using engineered bioluminescent viruses has emerged as a powerful tool for real-time, noninvasive monitoring of viral replication in living animals. While traditional luciferase-based systems, such as firefly luciferase, have been widely used, the NanoLuc luciferase system offers distinct advantages, including its significantly smaller gene size, increased brightness, and independence from ATP as a cofactor, allowing for extracellular detection. However, the utility of NanoLuc has been limited by its traditional substrate, furimazine, which exhibits poor water solubility and potential cytotoxicity.
View Article and Find Full Text PDFRecent advances in near-infrared organic photosensitizers for photodynamic cancer therapy.
Biomater Sci
January 2025
School of Chemistry and Life Sciences, Hanoi University of Science and Technology, 1 Dai Co Viet Road, Ha Noi, Vietnam.
With the advancement of photodynamic therapy, various photosensitizers have been developed to enhance the efficacy of cancer treatment while minimizing side effects. Recently, near-infrared organic fluorophores have gained significant attention as promising photodynamic agents for cancer therapy due to their tunable photophysical properties, structural versatility, good biocompatibility, high biosafety, and synthetic flexibility. In particular, near-infrared organic photosensitizers offer several notable advantages, including deep tissue penetration, a low fluorescence background for bioimaging, and reduced damage to biological tissues compared to traditional visible-spectrum photosensitizers.
View Article and Find Full Text PDFA multi-cohort study of longitudinal and cross-sectional Alzheimer's disease biomarkers in cognitively unimpaired older adults.
Alzheimers Dement
January 2025
Penn Memory Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Introduction: The generalizability of neuroimaging and cognitive biomarkers in their sensitivity to detect preclinical Alzheimer's disease (AD) and power to predict progression in large, multisite cohorts remains unclear.
Method: Longitudinal demographics, T1-weighted magnetic resonance imaging (MRI), and cognitive scores of 3036 cognitively unimpaired (CU) older adults (amyloid beta [Aβ]-negative/positive [A-/A+]: 1270/1558) were included. Cross-sectional and longitudinal cognition and medial temporal lobe (MTL) structural measures were extracted.
Background: Targeting glutamine metabolism has emerged as a promising strategy in cancer therapy. However, several barriers, such as anti-tumor efficacy, drug toxicity, and safety, remain to be overcome to achieve clinical utility. Prior preclinical studies had generated encouraging data showing promises of cancer metabolism targeting drugs, although most were performed on immune-deficient murine models.
View Article and Find Full Text PDFUnlabelled: Electric fields used in clinical trials with transcranial direct current stimulation (tDCS) are small, with magnitudes that have yet to demonstrate measurable effects in preclinical animal models. We hypothesized that weak stimulation will nevertheless produce sizable effects, provided that it is applied concurrently with behavioral training, and repeated over multiple sessions. We tested this here in a rodent model of dexterous motor-skill learning.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!